Patient Outcome Case Studies

Browse cases by condition and scale

Each case shows the validated outcome scale used, the baseline presentation, the protocol delivered in Istanbul, structured follow-up at Days 30/90/180/365 where available, and any adverse events observed. All patient identifiers are removed. These cases are illustrative, not predictive.

• WOMAC · United Kingdom

  Knee Osteoarthritis

  F, age band 55–64, United Kingdom

  Twelve-month structured follow-up of a UK patient with grade III bilateral knee osteoarthritis, tracked on the WOMAC Index after a Wharton's Jelly MSC program in Istanbul.

  Read case study
• EDSS · United States

  Multiple Sclerosis (Relapsing-Remitting)

  M, age band 40–49, United States

  Twelve-month EDSS follow-up for a US patient with relapsing-remitting MS who underwent an intravenous plus intrathecal Wharton's Jelly MSC protocol in Istanbul.

  Read case study
• ATEC · United Arab Emirates

  Autism Spectrum Disorder

  M, age 6–8, United Arab Emirates

  Twelve-month ATEC follow-up of a pediatric patient with non-verbal autism spectrum disorder following a Wharton's Jelly MSC protocol in Istanbul.

  Read case study
• DAS28 · Germany

  Rheumatoid Arthritis

  F, age band 45–54, Germany

  DAS28 follow-up over 12 months for a German patient with seropositive rheumatoid arthritis treated with an intravenous Wharton's Jelly MSC autoimmune program in Istanbul.

  Read case study
• anti-TPO · Canada

  Hashimoto's Thyroiditis

  F, age band 35–44, Canada

  Twelve-month tracking of anti-TPO antibody levels and TSH for a Canadian patient with Hashimoto's thyroiditis following a Wharton's Jelly MSC autoimmune protocol in Istanbul.

  Read case study
• HbA1c · Saudi Arabia

  Type 2 Diabetes Mellitus

  M, age band 50–59, Saudi Arabia

  Twelve-month HbA1c follow-up of a Saudi Arabian patient with type 2 diabetes treated under a Wharton's Jelly MSC metabolic protocol in Istanbul.

  Read case study